MAP Pharmaceuticals’ initial Phase III trial of Unit Dose Budesonide (UDB) for the potential treatment of pediatric asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime symptom scores, in either of the doses evaluated when compared with placebo.
 
AstraZeneca and MAP have a collaboration agreement to develop and commercialize UDB. The two companies will further analyze the data to determine appropriate next steps for the program.